Aldeyra's Reproxalap has Experts Mixed on Seasonal Allergic Conjunctivitis Focus in Phase III
Biopharmaceutical Report I Issue18_December 2018 Aldeyra Therapeutics’ (NASDAQ:ALDX) focus on seasonal allergies in its Phase III study...
top of page
BioPharmaceutical
Report
- Mar 19, 2019
Eisai's Lenvima for First-line HCC Is Approvable but Noninferiority Data to SOC May Slow Uptake
Biopharmaceutical Report II Issue17_July 2018 Eisai’s (TYO:4523) Lenvima (lenvatinib) has a clear path to approval in first-line...
- Mar 12, 2019
Immunomedics’ Sacituzumab Has Insufficient Dataset to Pursue Accelerated Approval
Biopharmaceutical Report I Issue17_July 2018 Immunomedics’ (NASDAQ:IMMU) Phase I/ II sacituzumab govitecan hormone receptor positive...
- Mar 12, 2019
Shooting for the Universe
Biopharmaceutical Report III Issue16_April 2018 SHOOTING FOR THE UNIVERSE By Michael Leviten, Senior Writer CureVac AG is bringing a new...
- Mar 12, 2019
Biosimilar Uptake Still Plagued by Interchangeability Hurdles
Biopharmaceutical Report II Issue17_July 2018 Biosimilar interchangeability with reference biologics remains a challenge years after...
- Mar 12, 2019
Alnylam vs Dicerna Trade Secret Litigation May Be Influenced by Emotive Arguments
Biopharmaceutical Report I Issue16_April 2018 Alnylam’s (NASDAQ:ALNY) trade secrets litigation case against Dicerna (NASDAQ:DRNA) could...
- Mar 12, 2019
BeiGene’s Phase III BGB-3111 in WMHas Unclear Efficacy Advantage Over Imbruvica
Biopharmaceutical Report II Issue15_November 2017 BeiGene’s (NASDAQ:BGNE) BGB-3111 for Waldenström’s macroglobulinemia (WM) will need...
- Mar 12, 2019
Corbus’ Phase II Anabasum in Dermatomyositis Garners Mixed Expert Expectations
Biopharmaceutical Report I Issue15_November 2017 Corbus Pharmaceuticals’ (NASDAQ:CRBP) Phase II study of anabasum in skin-predominant...
- Mar 12, 2019
Strategic Shift of Dong-A ST Co. Ltd. in Drug Discovery
Biopharmaceutical Report III Issue14_July 2017 BY EMILY CUKIER-MEISNER, SENIOR WRITER Dong-A ST Co. Ltd. has spent the last four years...
- Mar 12, 2019
Medical Device: Growing Cybersecurity Threat and Need for More Regulation
Biopharmaceutical Report II Issue14_July 2017 Despite an expected increase in the frequency in cybersecurity threats in the near future...
- Mar 12, 2019
Eisai’s Lenvima Should See FDA Approval in Hepatocellular Carcinoma (HCC)
Biopharmaceutical Report I Issue15_July 2017 • Valuations unreliable given large timeframe to market • Likely EU/US pricing pressures...
- Mar 12, 2019
Western CAR-Ts face Chinese Development Hurdles Due to Regulatory Uncertainty
Biopharmaceutical Report II Issue13_April 2017 Western-origin chimeric antigen receptor T-cell (CAR-T) therapies being developed in China...
- Mar 12, 2019
Legislation to Force Payer Coverage of AbuseDeterrent Opioids Faces Resistance
Biopharmaceutical Report I Issue13_April 2017 Proposed legislation across 23 US states to force payers to increase reimbursement of...
- Mar 12, 2019
Roche’s GALLIUM Results Draw Skepticism about Changing Practice in First-Line Follicular Lymphoma
Biopharmaceutical Report III Issue12_December 2016 Roche’s (VTX:ROG) Phase III GALLIUM study of Gazyva (obinutuzumab) in first-line...
- Mar 12, 2019
Humira Biosimilar Unlikely to Reach the Market Before 2020
Biopharmaceutical Report II Issue12_December 2016 The numerous biosimilars for AbbVie’s (NYSE:ABBV) Humira (adalimumab) are unlikely...
bottom of page